LYEL
Lyell Immunopharma, Inc.$14.49+1.05 (+7.87%)Prev Close$13.40·MCap$279.3M·P/E—·Vol120.0K·Yield—
▲
Buys (12M)
2
$25.00M
▼
Sells (12M)
23
$508.7K
◆
Net Activity
Net Buyer
$24.49M
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Lyell Immunopharma, Inc. (LYEL) has been dominated by buying, with 2 insider purchases totaling $25.00M and 23 insider sales totaling $508.7K. The most recent insider transaction was by Seely Lynn (director, officer: President and CEO), who sold $7.3K worth of shares on Jun 15, 2026. Lyell Immunopharma, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $279.3M.
LYEL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Seely Lynn | director, officer: President and CEO | Sell | 388 | $18.91 | $7.3K | 73,878 |
| Jun 15, 2026 | Hill Stephen J. | officer: Chief Operating Officer | Sell | 89 | $18.92 | $1.7K | 17,894 |
| Jun 15, 2026 | Lee Gary K. | officer: Chief Scientific Officer | Sell | 130 | $18.92 | $2.5K | 17,808 |
| Jun 15, 2026 | Bulis Veronica Sanchez | officer: VP, Corporate Controller | Sell | 217 | $18.91 | $4.1K | 15,420 |
| Jun 11, 2026 | Shook David | officer: Chief Medical Officer | Sell | 1,977 | $12.64 | $25.0K | 20,923 |
| Mar 9, 2026 | ARCH Venture Fund XIII, L.P. | 10 percent owner | Buy | 488,090 | $25.61 | $12.50M2.1% OS | 1,426,528+52% |
| Mar 9, 2026 | ARCH Venture Partners IX, LLC | 10 percent owner | Buy | 488,090 | $25.61 | $12.50M2.1% OS | 1,426,528+52% |
| Feb 11, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | 1,236 | $23.39 | $28.9K | 0 |
| Feb 11, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | 1,671 | $23.39 | $39.1K | 0 |
| Feb 11, 2026 | Seely Lynn | President and CEO | Sell | 7,455 | $23.39 | $174.4K | 0 |
| Feb 10, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 254 | $23.12 | $5.9K | 0 |
| Feb 9, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | 109 | $23.12 | $2.5K | 0 |
| Feb 9, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | 147 | $23.12 | $3.4K | 0 |
| Feb 9, 2026 | Seely Lynn | President and CEO | Sell | 438 | $23.12 | $10.1K | 0 |
| Dec 24, 2025 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 2,072 | $35.80 | $74.2K | 0 |
| Nov 10, 2025 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 239 | $16.10 | $3.8K | 0 |
| Nov 10, 2025 | Hill Stephen J. | Chief Operating Officer | Sell | 95 | $16.12 | $1.5K | 0 |
| Nov 10, 2025 | Lee Gary K. | Chief Scientific Officer | Sell | 138 | $16.16 | $2.2K | 0 |
| Nov 10, 2025 | Seely Lynn | President and CEO | Sell | 412 | $16.11 | $6.6K | 0 |
| Aug 20, 2025 | Hill Stephen J. | Chief Operating Officer | Sell | 1,004 | $10.54 | $10.6K | 0 |
| Aug 20, 2025 | Newton Charles W. | Chief Financial Officer | Sell | 1,453 | $10.54 | $15.3K | 0 |
| Aug 20, 2025 | Seely Lynn | President and CEO | Sell | 7,257 | $10.54 | $76.5K | 0 |
| Aug 11, 2025 | Hill Stephen J. | Chief Operating Officer | Sell | 185 | $10.43 | $1.9K | 0 |
| Aug 11, 2025 | Lee Gary K. | Chief Scientific Officer | Sell | 267 | $10.43 | $2.8K | 0 |
| Aug 11, 2025 | Seely Lynn | President and CEO | Sell | 797 | $10.43 | $8.3K | 0 |
| Mar 31, 2025 | BRAWLEY OTIS W | Director | Buy | 35,640 | $0.56 | $20.0K | 0 |
| Mar 21, 2025 | Ramachandra Sumant | Director | Buy | 200,000 | $0.58 | $115.2K0.9% OS | 0 |
| Mar 17, 2025 | Newton Charles W. | Chief Financial Officer | Buy | 200,000 | $0.56 | $111.6K0.9% OS | 0 |
| Mar 14, 2025 | Klausner Richard | Director | Buy | 158,000 | $0.60 | $94.9K0.7% OS | 0 |
| Mar 14, 2025 | Seely Lynn | President and CEO | Buy | 175,000 | $0.61 | $106.2K0.8% OS | 0 |
| Aug 17, 2023 | Klausner Richard | Director | Sell | 58,020 | $2.28 | $132.3K | 930,880 |
| Sep 27, 2022 | Klausner Richard | Director | Sell | 11,100 | $6.40 | $71.0K | 988,900 |
| Jun 23, 2021 | FRIEDMAN CATHY | Director | Buy | 17,648 | $17.00 | $300.0K | 17,648 |
LYEL Insider Buying Activity
The following table shows recent insider purchases of Lyell Immunopharma, Inc. (LYEL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | ARCH Venture Fund XIII, L.P. | 10 percent owner | Buy | 488,090 | $25.61 | $12.50M2.1% OS | 1,426,528+52% |
| Mar 9, 2026 | ARCH Venture Partners IX, LLC | 10 percent owner | Buy | 488,090 | $25.61 | $12.50M2.1% OS | 1,426,528+52% |
| Mar 31, 2025 | BRAWLEY OTIS W | Director | Buy | 35,640 | $0.56 | $20.0K | 0 |
| Mar 21, 2025 | Ramachandra Sumant | Director | Buy | 200,000 | $0.58 | $115.2K0.9% OS | 0 |
| Mar 17, 2025 | Newton Charles W. | Chief Financial Officer | Buy | 200,000 | $0.56 | $111.6K0.9% OS | 0 |
| Mar 14, 2025 | Klausner Richard | Director | Buy | 158,000 | $0.60 | $94.9K0.7% OS | 0 |
| Mar 14, 2025 | Seely Lynn | President and CEO | Buy | 175,000 | $0.61 | $106.2K0.8% OS | 0 |
| Jun 23, 2021 | FRIEDMAN CATHY | Director | Buy | 17,648 | $17.00 | $300.0K | 17,648 |
LYEL Insider Selling Activity
The following table shows recent insider sales of Lyell Immunopharma, Inc. (LYEL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Seely Lynn | director, officer: President and CEO | Sell | 388 | $18.91 | $7.3K | 73,878 |
| Jun 15, 2026 | Hill Stephen J. | officer: Chief Operating Officer | Sell | 89 | $18.92 | $1.7K | 17,894 |
| Jun 15, 2026 | Lee Gary K. | officer: Chief Scientific Officer | Sell | 130 | $18.92 | $2.5K | 17,808 |
| Jun 15, 2026 | Bulis Veronica Sanchez | officer: VP, Corporate Controller | Sell | 217 | $18.91 | $4.1K | 15,420 |
| Jun 11, 2026 | Shook David | officer: Chief Medical Officer | Sell | 1,977 | $12.64 | $25.0K | 20,923 |
| Feb 11, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | 1,236 | $23.39 | $28.9K | 0 |
| Feb 11, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | 1,671 | $23.39 | $39.1K | 0 |
| Feb 11, 2026 | Seely Lynn | President and CEO | Sell | 7,455 | $23.39 | $174.4K | 0 |
| Feb 10, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 254 | $23.12 | $5.9K | 0 |
| Feb 9, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | 109 | $23.12 | $2.5K | 0 |
| Feb 9, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | 147 | $23.12 | $3.4K | 0 |
| Feb 9, 2026 | Seely Lynn | President and CEO | Sell | 438 | $23.12 | $10.1K | 0 |
| Dec 24, 2025 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 2,072 | $35.80 | $74.2K | 0 |
| Nov 10, 2025 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 239 | $16.10 | $3.8K | 0 |
| Nov 10, 2025 | Hill Stephen J. | Chief Operating Officer | Sell | 95 | $16.12 | $1.5K | 0 |
| Nov 10, 2025 | Lee Gary K. | Chief Scientific Officer | Sell | 138 | $16.16 | $2.2K | 0 |
| Nov 10, 2025 | Seely Lynn | President and CEO | Sell | 412 | $16.11 | $6.6K | 0 |
| Aug 20, 2025 | Hill Stephen J. | Chief Operating Officer | Sell | 1,004 | $10.54 | $10.6K | 0 |
| Aug 20, 2025 | Newton Charles W. | Chief Financial Officer | Sell | 1,453 | $10.54 | $15.3K | 0 |
| Aug 20, 2025 | Seely Lynn | President and CEO | Sell | 7,257 | $10.54 | $76.5K | 0 |
| Aug 11, 2025 | Hill Stephen J. | Chief Operating Officer | Sell | 185 | $10.43 | $1.9K | 0 |
| Aug 11, 2025 | Lee Gary K. | Chief Scientific Officer | Sell | 267 | $10.43 | $2.8K | 0 |
| Aug 11, 2025 | Seely Lynn | President and CEO | Sell | 797 | $10.43 | $8.3K | 0 |
| Aug 17, 2023 | Klausner Richard | Director | Sell | 58,020 | $2.28 | $132.3K | 930,880 |
| Sep 27, 2022 | Klausner Richard | Director | Sell | 11,100 | $6.40 | $71.0K | 988,900 |
LYEL Insiders
Similar Stocks to LYEL
VRTX
Vertex Pharmaceuticals Incorporated
$476.29+0.08%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$662.73+1.01%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$275.93-1.72%
$43.19B
RVMD
Revolution Medicines, Inc.
$185.71+0.42%
$40.34B
MRNA
Moderna, Inc.
$68.11+1.00%
$27.09B
INSM
Insmed Incorporated
$109.25-0.67%
$25.06B
INCY
Incyte Corporation
$114.43-0.30%
$23.32B
UTHR
United Therapeutics Corporation
$530.63+0.75%
$23.22B